Show simple item record

dc.contributor.advisorOlmos, Carlos 
dc.contributor.advisorJagua, Andrés 
dc.creatorRodriguez Ossa, Sandra Patricia 
dc.creatorAguilera Martinez, Sara 
dc.date.accessioned2013-01-30T19:43:30Z
dc.date.available2013-01-30T19:43:30Z
dc.date.created2012-11-30
dc.date.issued2012
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/4150
dc.descriptionLas infecciones respiratorias altas y bajas son una causa común de morbimortalidad infantil. Se ha propuesto el uso de los lisados bacterianos para prevenir las infecciones recurrentes sin embargo su uso aún se considera controversial. Metodología: Se realizó una revisión sistemática de la literatura. La búsqueda se realizó a través de las bases de datos PUBMED, Embase, Ovid, LiLaCS y Cochrane library plus. Se incluyeron metanálisis publicados en idiomas inglés y español, entre los años 1998 y 2012. Se realizó una evaluación de calidad siguiendo la estrategia Quorum y un análisis cualitativo y cuantitativo de los resultados. Resultados: Se incluyeron 4 revisiones sistemáticas de la literatura con metanálisis. Fue apreciable la disminución de las recurrencias de las infecciones respiratorias relacionadas con el uso de los lisados bacterianos. Los lisados bacterianos disminuyen la necesidad de uso de antibióticos. No se encontró evidencia sobre el uso de los lisados sobre desenlaces como la necesidad de intervenciones adicionales, tiempo de hospitalización, costo relacionado con la atención en salud. No se reportaron eventos adversos de importancia. Conclusión: Los lisados bacterianos son eficaces en disminuir la recurrencia de las infecciones respiratorias en pacientes en edad pediátrica.
dc.description.abstractThe upper and lower respiratory infections are a common cause of childhood morbidity and mortality. It has proposed the use of bacterial lysates to prevent recurrent infections even though their use is considered controversial. Methodology: We conducted a systematic review of the literature. The search was performed using the databases PubMed, Embase, Ovid, Lilacs and Cochrane Library. We included meta-analyzes published in English and Spanish, between 1998 and 2012. An evaluation of quality following the strategy Quorum and qualitative and quantitative analysis of the results. Results: We included 4 systematic reviews of the literature with meta-analysis. Was appreciably reduced recurrences of respiratory infections related to the use of bacterial lysates. The bacterial lysates reduce the need for antibiotics. There was no evidence on the use of the lysates on outcomes such as the need for additional interventions, length of stay, costs related to health care. There were no significant adverse events. Conclusion: The bacterial lysates are effective in reducing the recurrence of respiratory infections in pediatric patients.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.sourcereponame:Repositorio Institucional EdocUR
dc.sourceinstname:Universidad del Rosario
dc.subjectLisado bacteriano
dc.subjectniños
dc.subjectinfecciones respiratorias
dc.subjectprevención y control
dc.subjectrevisión sistemática
dc.subject.lembAdyuvantes inmunológicos::Uso Terapéutico
dc.subject.lembEnfermedades respiratorias pediátricas
dc.subject.lembInfecciones respiratorias en niños::Tratamiento
dc.titleUso de lisados bacterianos en la prevención de la infección respiratoria recurrente en pediatría. Revisión sistemática de la literatura
dc.typemasterThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Pediatría
dc.publisher.programEspecialización en Pediatría
dc.publisher.departmentFacultad de medicina
dc.subject.keywordBacterial lysate
dc.subject.keywordchildren
dc.subject.keywordrespiratory infection
dc.subject.keywordprevention and control
dc.subject.keywordsystematic review
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitation1. Sadhi SA, De Wals P, Grijalva CG, Grimwood K, Grossman R, Ishiwada N, et al. The Burden of Childhood Pneumonia in the Developed World: A Review of the Literature. Pediatr Infect Dis J 2012. En prensa
dc.source.bibliographicCitation2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375 (9725): 1545-1555
dc.source.bibliographicCitation3. Chang AB, Chang CC, O'Grady K, Torzillo PJ. Lower respiratory tract infections. Pediatr Clin North Am 2009; 56 (6): 1303-1321
dc.source.bibliographicCitation4. Fioscchi A, Terracciano L, Martelli A, Bernardo L, Calcinai E, Marcassa S. Ribosome-component immune modulation of respiratory tract infections in children,.Allergy Asthma Proc 1009; 30:S21–S31.
dc.source.bibliographicCitation5. Fiocchi A, Omboni S, Mora R, Macchi A, Nespoli L, Arrigoni S, Guastini L, et al. Efficacy and safety of ribosome-component immune modulator for preventing recurrent respiratory infections in socialized children, Allergy Asthma Proc 2012; 33:197–204.
dc.source.bibliographicCitation6. Leiva LE, Monjure H, Sorensen RU. Recurrent Respiratory Infections, Specific Antibody Deficiencies, and Memory B Cells. J Clin Immunol 2012. En prensa.
dc.source.bibliographicCitation7. Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: a meta-analysis. Pulm Pharmacol Ther. 2012; 25 (1): 62-68.
dc.source.bibliographicCitation8. Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica GW. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis 2007;2 (3): 335-345.
dc.source.bibliographicCitation9. Steurer-Stey C, Lagler L, Straub DA, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr 2007; 166 (4): 365-76.
dc.source.bibliographicCitation10. Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants--mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol 2008; 76 (5): 353-359.
dc.source.bibliographicCitation11. Olmos C, Lozano MI, Quijano CL. Infecciones recurrentes y sospecha de inmunodeficiencias primarias. Precop CCAP 2011; 11: 5-15.
dc.source.bibliographicCitation12. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989; 160 (1): 83-94.
dc.source.bibliographicCitation13. Brook I, and Gobler AE. Dynamics of nasopharyngitis in children. Otolaryngol Head Neck Surg 2000; 122:696 –700.
dc.source.bibliographicCitation14. International Rhinitis Management Working Group. International Consensus Report on the diagnosis and management of rhinitis. Allergy. 1994;49(19 Suppl):1-34
dc.source.bibliographicCitation15. Graham NM. The epidemiology of acute respiratory infections in children and adults: A global perspective. Epidemiol Rev 1990; 12: 149 –178.
dc.source.bibliographicCitation16. AIEPI, Atención integrada a las enfermedades prevalentes de la infancia, 2011.
dc.source.bibliographicCitation17. Chantry CJ, Howard CR, and Auinger P. Full breastfeeding duration and associated decrease in respiratory tract infection in US children. Pediatrics 2006; 117:425– 432.
dc.source.bibliographicCitation18. Trosini-Desert V, Germaud P, and Dautzenberg B. Tobacco smoke and risk of bacterial infection. Rev Mal Respir 2004; 21:539– 554.
dc.source.bibliographicCitation19. Morales de leon J, Acosta D, Anaya F, De la cruz Pinzón C Escamilla JM, et al. Infección respiratoria alta. Guias de practica clinica basadas en la evidencia. Ascofame. La institución. Bogota
dc.source.bibliographicCitation20. Braido F, Tarantini F, Ghiglione V, Melioli G, Canonica GW. Bacterial lysate in the prevention of acute exacerbation of COPD and in respiratory recurrent infections. Int J Chron Obstruct Pulmon Dis 2007; 2 (3): 335-345.
dc.source.bibliographicCitation21. Rozy A, Chorostowska-Wynimko J. Bacterial immunostimulants--mechanism of action and clinical application in respiratory diseases. Pneumonol Alergol Pol 2008; 76 (5): 353-9.
dc.source.bibliographicCitation22. Mihălţan F, Popescu O. Broncho-vaxom, representative drug of a new therapeutical concept in lung pathology (present and future outlooks). Pneumoftiziologia 1991; 40 (1): 25-33
dc.source.bibliographicCitation23. Mauël J. Stimulation of immunoprotective mechanisms by OM-85 BV. A review of results from in vivo and in vitro studies. Respiration 1994;61 Suppl 1:8-15
dc.source.bibliographicCitation24. Allard JB, Rinaldi L, Wargo MJ, Allen G, Akira S, Uematsu S, et al. Th2 allergic immune response to inhaled fungal antigens is modulated by TLR-4-independent bacterial products. Eur J Immunol. 2009; 39 (3): 776-88.
dc.source.bibliographicCitation25. Linnebacher M, Maletzki C, Emmrich J, Kreikemeyer B. Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. J Immunother. 2008 ; 31 (8): 704-13.
dc.source.bibliographicCitation26. Mauel J, Van Pham T, Kreis B, Bauer J. Stimulation by a bacterial extract (Broncho-Vaxom) of the metabolic and functional activities of murine macrophages. Int J Immunopharmacol 1989; 11 (6): 637-45.
dc.source.bibliographicCitation27. Morandi B, Agazzi A, D'Agostino A, Antonini F, Costa G, Sabatini F, A mixture of bacterial mechanical lysates is more efficient than single strain lysate and of bacterial-derived soluble products for the induction of an activating phenotype in human dendritic cells. Immunol Lett 2011; 138 (1): 86-91
dc.source.bibliographicCitation28. Ruedl C, Frühwirth M, Wick G, Wolf H. Immune response in the lungs following oral immunization with bacterial lysates of respiratory pathogens. Clin Diagn Lab Immunol 1994;1 (2): 150-4.
dc.source.bibliographicCitation29. Rossi GA, Peri C, Raynal ME, Defilippi AC, Risso FM, Schenone G, et al. Naturally occurring immune response against bacteria commonly involved in upper respiratory tract infections: analysis of the antigen-specific salivary IgA levels. Immunol Lett 2003; 86 (1): 85-91
dc.source.bibliographicCitation30. ALTANA PHARMA, S.A. DE C.V. Av. Primero De Mayo Núm. 130, http://www.libreriamedica8a.com/productos/376.htm
dc.source.bibliographicCitation31. PIERRE FABRE MEDICAMENT, http://www.medicamentos.com.mx/DocHTM/27571.htm
dc.source.bibliographicCitation32. Del-Río-Navarro BE, Luis Sienra-Monge JJ, Berber A, Torres-Alcántara S, Avila-Castañón L, Gómez-Barreto D. Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergol Immunopathol (Madr) 2003; 31 (1): 7-13.
dc.source.bibliographicCitation33. RUDEFSA, S.A. DE C.V. ftp://148.228.156.172/pub/Programas/Programas%20psicologia/PLM-DEF52/prods/36013.htm
dc.source.bibliographicCitation34. http://mx.prvademecum.com/producto.php?producto=11433
dc.source.bibliographicCitation35. Pessey JJ, Mégas F, Arnould B, Baron-Papillon F. Prevention of recurrent rhinopharyngitis in at-risk children in France: a cost-effectiveness model for a nonspecific immunostimulating bacterial extract (OM-85 BV). Pharmacoeconomics 2003; 21 (14): 1053-68.
dc.source.bibliographicCitation36. Fiocchi A, Olivieri D, Marcassa S, Zava D, Robberto E. Cost effective analysis of ribosome-component immune modulation. Allergy Asthma Proc. 2009;30 Suppl 1:S37-9.
dc.source.bibliographicCitation37. Cazzola M, Anapurapu S, Page CP. Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infections: A meta-analysis. Pulmonary Pharmacol Ther 2012; 25: 62-68
dc.source.bibliographicCitation38. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJL. Immunostimulants for preventing respiratory tract infection in children. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004974. DOI: 10.1002/14651858.CD004974.pub2.
dc.source.bibliographicCitation39. Schaad UB. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr 2010; 6(1): 5-12.
dc.source.bibliographicCitation40. Steurer-Stey C, Lagler L, sTRAUB da, Steurer J, Bachmann LM. Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. Eur J Pediatr 2007; 166: 365-376.
dc.source.bibliographicCitation41. Derenne JP, Delclaux B. Clinical experience with OM-85 BV in upper and lower respiratory tract infections. Respiration. 1992;59 Suppl 3:28-31.
dc.format.tipoDocumento
dc.rights.ccAtribución-NoComercial-SinDerivadas 2.5 Colombia
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe.


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/